Machine Learning Technology for Evaluation of Liver Fibrosis, Inflammation Activity and Steatosis (LIVERFASt™)

Comparative 10-Years Prognosis of Fibrotest (FT) and Liver Stiffness Measurement (LSM) by Transient Elastog-raphy (TE, Fibroscan) in 9364 Chronic Liver Diseases (CLD) Patients (Pts)

Comparison of 16 blood and/or elastometric fibrosis tests in 5 causes of chronic liver diseases: too much? Towards a simplification

Liver Fibrosis Epidemiology Revisited Using Software Combined Biomarker: Proof of Concept Using 1,081,658 Centralised Fibrotest (FT) Prescriptions